Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | HNF4A | P41235 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7195291 | 0.86 | HNF4A (0.55) | HPGDALDH1A1MCL1BCL2CYP3A4 | |
| SCHEMBL1039389 | 0.81 | HPGD (0.56) | HPGDALDH1A1MAOBMCL1BCL2 | |
| SCHEMBL1020499 | 0.78 | MCL1 (0.56) | HPGDALDH1A1MAOBMCL1CYP3A4 | |
| SCHEMBL15220064 | 0.77 | ALDH1A1 (0.59) | HPGDALDH1A1MCL1CYP3A4MAPK1 | |
| SCHEMBL7196389 | 0.75 | BCL2 (0.59) | HPGDALDH1A1MAOBMCL1BCL2 | |
| SCHEMBL3196569 | 0.75 | MCL1 (0.62) | HPGDALDH1A1MCL1BCL2CYP3A4 | |
| SCHEMBL522901 | 0.74 | KDM4E (0.61) | HPGDALDH1A1MAOBMCL1BCL2 | |
| SCHEMBL30003813 | 0.74 | ALDH1A1 (0.47) | HPGDALDH1A1MAOBCYP3A4MAPK1 | |
| SCHEMBL21950992 | 0.74 | ALDH1A1 (0.47) | HPGDALDH1A1MAOBMCL1CYP3A4 | |
| SCHEMBL21951042 | 0.74 | ALDH1A1 (0.47) | HPGDALDH1A1MAOBCYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027104-B1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| EP-2027104-B1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7754759-B2 | Arylsulfonyl chromans as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754759-B2 | Arylsulfonyl chromans as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754759-B2 | Arylsulfonyl chromans as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| EP-2027104-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007051735-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007051735-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | HTR6, HTR1F, HTR1A | HPGD 2346/4885ALDH1A1 1927/4885MAOB 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.